Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression
about
Recent advances in targeting the autotaxin-lysophosphatidate-lipid phosphate phosphatase axis in vivoReal-time motion analysis reveals cell directionality as an indicator of breast cancer progressionTargeted deletion of LPA5 identifies novel roles for lysophosphatidic acid signaling in development of neuropathic painExome analysis reveals differentially mutated gene signatures of stage, grade and subtype in breast cancers.Minireview: recent developments in the physiology and pathology of the lysophosphatidylinositol-sensitive receptor GPR55.Lysophosphatidic acid induces MDA-MB-231 breast cancer cells migration through activation of PI3K/PAK1/ERK signaling.Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.Activated networking of platelet activating factor receptor and FAK/STAT1 induces malignant potential in BRCA1-mutant at-risk ovarian epithelium.Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy.Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells.Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper proteinA critical role of Gbetagamma in tumorigenesis and metastasis of breast cancer.Mitogenic Signaling by the gep Oncogene Involves the Upregulation of S-Phase Kinase-Associated Protein 2.CARMA3: A novel scaffold protein in regulation of NF-κB activation and diseasesAromatic phosphonates inhibit the lysophospholipase D activity of autotaxinMetabolic Signatures of Human Breast Cancer.Small lipidated anti-obesity compounds derived from neuromedin U.The autotaxin-lysophosphatidic acid-lysophosphatidic acid receptor cascade: proposal of a novel potential therapeutic target for treating glioblastoma multiformeAberrant expression and potential therapeutic target of lysophosphatidic acid receptor 3 in triple-negative breast cancers.Lysophosphatidic acid-induced p21Waf1 expression mediates the cytostatic response of breast and ovarian cancer cells to TGFβ.Expression of lysophosphatidic acid receptors and local invasiveness and metastasis in Chinese pancreatic cancers.Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progressionExpressions of lysophosphatidic acid receptors in the development of human ovarian carcinoma.Higher plasma levels of lysophosphatidylcholine 18:0 are related to a lower risk of common cancers in a prospective metabolomics studyMetabolic biomarkers for response to PI3K inhibition in basal-like breast cancer.The gep proto-oncogene Gα13 mediates lysophosphatidic acid-mediated migration of pancreatic cancer cells.Upregulated WDR26 serves as a scaffold to coordinate PI3K/ AKT pathway-driven breast cancer cell growth, migration, and invasion.Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8.PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune ToleranceLysophosphatidic acid (LPA) and endothelial differentiation gene (Edg) receptors in human pancreatic cancer.New insights regarding the regulation of chemotaxis by nucleotides, adenosine, and their receptors.The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer.Eicosopentaneoic Acid and Other Free Fatty Acid Receptor Agonists Inhibit Lysophosphatidic Acid- and Epidermal Growth Factor-Induced Proliferation of Human Breast Cancer CellsLPA signaling through LPA receptors regulates cellular functions of endothelial cells treated with anticancer drugs.Lipid remodelling in human melanoma cells in response to UVA exposure.Gene expression of the lysophosphatidic acid receptor 1 is a target of transforming growth factor beta.Opposite roles of LPA1 and LPA3 on cell motile and invasive activities of pancreatic cancer cells.Discovery and synthetic optimization of a novel scaffold for hydrophobic tunnel-targeted autotaxin inhibition.Lysophosphatidic acid receptor agonists and antagonists (WO2010051053).Choline-releasing glycerophosphodiesterase EDI3 links the tumor metabolome to signaling network activities.
P2860
Q26741062-C746F4CF-2E8F-444A-9388-36E8AAEE42B5Q27334635-CD6849AA-1EF8-49DC-8EDB-44A18CFC6BDBQ28585279-91BBA05D-F697-4CD8-9459-F82A8D2F3ABDQ30372977-FB8FF6D0-0E46-40CB-B0B0-F0779853975DQ33636763-D9D00CBA-DCA9-468B-BC8B-3F0E49C7EA96Q33786774-C2C2B341-3407-42CC-8D6E-DB9A36E16BC0Q33972424-C1C2B6AA-FF80-44BF-B47A-F6A539EF2AE6Q33992208-550EEDCE-AACE-4C03-8D23-C0E710FD4A9DQ34292377-EC9D7D95-982C-434A-9CEB-EA9153A868CBQ34387665-C2E42105-10A9-4135-83EB-3E4366225826Q34763681-6EBC09A3-C621-4809-8729-3F3BA2E3E9EEQ34787134-D4A1A02D-9C2A-4EBF-9564-A3531C117DEAQ34866982-69BB6F4F-84A7-470E-A6C5-0851D92373DAQ34878582-80090B61-EDD2-4B08-AE14-99DDC536A184Q35118841-C2FDD3F0-F4C1-4314-BC88-51AF9C029A0EQ35627478-19D58418-39F7-4DCF-A8A8-41DD2C9E3E54Q35708420-94EB15F3-A89C-4503-965F-07438E701780Q35770218-5A991F92-17D2-4C9A-BDEE-145EB944C5DCQ35908698-E2699214-10EA-4253-8CD9-787BEBE91DC6Q36073708-B3A53436-AE51-4CFC-9BD9-E09F991BF7DAQ36145321-F37EAB51-7B20-4EBC-93CC-DDEA368BFAB3Q36399256-D190BD15-D6C3-4D81-ACCA-2D79EC01DAF0Q36411668-E218C5E8-1B97-4722-B193-CCBBE8EAA899Q36513866-1021491D-463E-4D31-892A-D577F3D19390Q36903072-E75560C0-9AFB-473E-95B7-FE1F76972B0DQ36941344-4E20B44F-7BBC-4CC4-B9D2-8620402AA10FQ37109616-DAB29B73-676B-4D44-824F-FE5F4B1E963CQ37368282-C5237191-8B59-4E53-BA13-CCCCFE443F1BQ37547644-1C8E2E23-8CC2-4F9D-B487-4467C5D164B0Q37899821-B0C86A98-EE69-42A8-9205-53F3F426536EQ38005034-5BCDED8B-5445-4DEC-9043-015ADB8D64B4Q38246634-A8D32BB8-4972-4CE3-8F7F-2A50B3CD57A2Q38711479-F74337A5-C658-4459-96FA-EB595A6F5A62Q38859656-A1303240-43F5-4C03-95C2-3446E05E5A2AQ38901714-7CE0F2FC-D2CD-44C3-806E-5E2C69ECAF93Q39309657-E609138C-301F-4ACF-90C7-9A5AB7FBAD73Q39334937-18694830-51C5-4889-8628-DC820B160CBEQ41634425-F833212B-7994-4D32-ABFC-37F2819D0220Q42021207-F9B5B8F2-0C25-437B-B205-F98DDBB04C3AQ42039436-541361B5-8579-4E5A-A0F0-92660D3B1905
P2860
Lysophosphatidic acid production and action: critical new players in breast cancer initiation and progression
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Lysophosphatidic acid producti ...... cer initiation and progression
@ast
Lysophosphatidic acid producti ...... cer initiation and progression
@en
Lysophosphatidic acid producti ...... cer initiation and progression
@nl
type
label
Lysophosphatidic acid producti ...... cer initiation and progression
@ast
Lysophosphatidic acid producti ...... cer initiation and progression
@en
Lysophosphatidic acid producti ...... cer initiation and progression
@nl
prefLabel
Lysophosphatidic acid producti ...... cer initiation and progression
@ast
Lysophosphatidic acid producti ...... cer initiation and progression
@en
Lysophosphatidic acid producti ...... cer initiation and progression
@nl
P2093
P2860
P921
P356
P1476
Lysophosphatidic acid producti ...... cer initiation and progression
@en
P2093
P2860
P2888
P356
10.1038/SJ.BJC.6605588
P407
P577
2010-03-16T00:00:00Z
P5875
P6179
1040932252